Sheila A Alexander1, Dianxu Ren, Scott R Gunn, Patrick M Kochanek, Judith Tate, Milos Ikonomovic, Yvette P Conley. 1. All authors are at the University of Pittsburgh, Pittsburgh, Pennsylvania. Sheila A. Alexander and Dianxu Ren are assistant professors and Yvette P. Conley is an associate professor in the School of Nursing. Scott R. Gunn is an associate professor and Patrick M. Kochanek is a professor in the School of Medicine. Judith Tate is a postdoctoral fellow, Department of Psychology, and Milos Ikonomovic is a research assistant professor, Department of Neurology.
Abstract
BACKGROUND: Delirium occurs in up to 80% of intensive care patients and is associated with poor outcomes. The biological cause of delirium remains elusive. OBJECTIVES: To determine if delirium and recovery are associated with serum levels of interleukins and apolipoprotein E over time and with apolipoprotein E genotype. METHODS: The sample consisted of 77 patients with no previous cognitive deficits who required mechanical ventilation for 24 to 96 hours. Daily serum samples were obtained for enzyme-linked immunosorbent assay measurements of interleukins 6, 8, and 10 and apolipoprotein E. DNA extracted from blood was analyzed for apolipoprotein E genotyping. The Confusion Assessment Method for the Intensive Care Unit was administered daily on days 2 through 9. RESULTS: Among the 77 patients, 23% had no delirium, 46% experienced delirium, and 31% experienced coma. Additionally, 77% had delirium or coma (acute brain dysfunction), and compared with other patients, had fewer ventilator-free days (P = .03), longer stay (P = .04), higher care needs at discharge (P = .001), higher mortality (P = .02), and higher levels of interleukin 6 (P = .03), and the APOE*3/*3 apolipoprotein E genotype (P = .05). Serum levels of apolipoprotein E correlated with levels of interleukins 8 and 10. Patients with the E4 allele of apolipoprotein E had shorter duration of delirium (P = .02) and lower mortality (P = .03) than did patients without this allele. CONCLUSIONS: Apolipoprotein E plays a complex role in illness response and recovery in critically ill patients. The relationship between apolipoprotein E genotype and brain dysfunction and survival is unclear.
BACKGROUND:Delirium occurs in up to 80% of intensive care patients and is associated with poor outcomes. The biological cause of delirium remains elusive. OBJECTIVES: To determine if delirium and recovery are associated with serum levels of interleukins and apolipoprotein E over time and with apolipoprotein E genotype. METHODS: The sample consisted of 77 patients with no previous cognitive deficits who required mechanical ventilation for 24 to 96 hours. Daily serum samples were obtained for enzyme-linked immunosorbent assay measurements of interleukins 6, 8, and 10 and apolipoprotein E. DNA extracted from blood was analyzed for apolipoprotein E genotyping. The Confusion Assessment Method for the Intensive Care Unit was administered daily on days 2 through 9. RESULTS: Among the 77 patients, 23% had no delirium, 46% experienced delirium, and 31% experienced coma. Additionally, 77% had delirium or coma (acute brain dysfunction), and compared with other patients, had fewer ventilator-free days (P = .03), longer stay (P = .04), higher care needs at discharge (P = .001), higher mortality (P = .02), and higher levels of interleukin 6 (P = .03), and the APOE*3/*3 apolipoprotein E genotype (P = .05). Serum levels of apolipoprotein E correlated with levels of interleukins 8 and 10. Patients with the E4 allele of apolipoprotein E had shorter duration of delirium (P = .02) and lower mortality (P = .03) than did patients without this allele. CONCLUSIONS:Apolipoprotein E plays a complex role in illness response and recovery in critically illpatients. The relationship between apolipoprotein E genotype and brain dysfunction and survival is unclear.
Authors: Daniel T Laskowitz; Pingping Song; Haichen Wang; Brian Mace; Patrick M Sullivan; Michael P Vitek; Hana N Dawson Journal: J Neurotrauma Date: 2010-11-02 Impact factor: 5.269
Authors: E W Ely; S K Inouye; G R Bernard; S Gordon; J Francis; L May; B Truman; T Speroff; S Gautam; R Margolin; R P Hart; R Dittus Journal: JAMA Date: 2001-12-05 Impact factor: 56.272
Authors: John R Lynch; Haichen Wang; Brian Mace; Stephen Leinenweber; David S Warner; Ellen R Bennett; Michael P Vitek; Suzanne McKenna; Daniel T Laskowitz Journal: Exp Neurol Date: 2005-03 Impact factor: 5.330
Authors: Joost Witlox; Lisa S M Eurelings; Jos F M de Jonghe; Kees J Kalisvaart; Piet Eikelenboom; Willem A van Gool Journal: JAMA Date: 2010-07-28 Impact factor: 56.272
Authors: Barbara C van Munster; Johanna C Korevaar; Aeilko H Zwinderman; Mariska M Leeflang; Sophia E J A de Rooij Journal: Am J Geriatr Psychiatry Date: 2009-10 Impact factor: 4.105
Authors: James L Rudolph; Basel Ramlawi; George A Kuchel; Janet E McElhaney; Dongxu Xie; Frank W Sellke; Kamal Khabbaz; Sue E Levkoff; Edward R Marcantonio Journal: J Gerontol A Biol Sci Med Sci Date: 2008-02 Impact factor: 6.053
Authors: Sarinnapha M Vasunilashorn; Long H Ngo; Sharon K Inouye; Tamara G Fong; Richard N Jones; Simon T Dillon; Towia A Libermann; Margaret O'Connor; Steven E Arnold; Zhongcong Xie; Edward R Marcantonio Journal: Alzheimers Dement Date: 2020-01-04 Impact factor: 21.566
Authors: Babar A Khan; Anthony J Perkins; Nagendra K Prasad; Anantha Shekhar; Noll L Campbell; Sujuan Gao; Sophia Wang; Sikandar H Khan; Edward R Marcantonio; Homer L Twigg; Malaz A Boustani Journal: Crit Care Med Date: 2020-03 Impact factor: 7.598
Authors: Koen S Simons; Mark van den Boogaard; Eva Hendriksen; Jelle Gerretsen; Johannes G van der Hoeven; Peter Pickkers; Cornelis P C de Jager Journal: Crit Care Date: 2018-05-25 Impact factor: 9.097
Authors: Mohamed D Hashem; Ramona O Hopkins; Elizabeth Colantuoni; Victor D Dinglas; Pratik Sinha; Lisa Aronson Friedman; Peter E Morris; James C Jackson; Catherine L Hough; Carolyn S Calfee; Dale M Needham Journal: Thorax Date: 2021-06-10 Impact factor: 9.139